Health Care·Life Sciences Tools & Services·$2.2B
Adaptive Biotechnologies (ADPT) specializes in innovative life sciences tools and services, focusing on using immune system data to improve health outcomes. As part of the healthcare sector, the company plays a crucial role in advancing personalized medicine and diagnostics.
EPS (Earnings Per Share)
EPS is a key indicator of profitability and will help gauge how well the company is managing its costs.
Revenue Growth
Although specific revenue figures are not available, growth in revenue is essential for demonstrating market demand and operational success.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+36.57%
Avg Stock Reaction
-0.71%
In the last quarter, Adaptive Biotechnologies reported an EPS of -0.09, outperforming expectations by 52.63%. However, the stock dropped 4.80% the following day, indicating mixed investor sentiment.
Management Promises & Guidance
Investors are cautiously optimistic about Adaptive's upcoming earnings, given their history of beating EPS estimates. However, the lack of revenue guidance adds uncertainty.
Bull Case
If Adaptive continues its trend of beating EPS estimates and shows signs of revenue growth, it could signal strong demand for its products, leading to a positive stock reaction.
Bear Case
On the other hand, if the company fails to provide clear guidance or reports disappointing metrics, it could lead to a sell-off, especially given the recent stock performance.
EPS (Earnings Per Share)
N/AEPS is a key indicator of profitability and will help gauge how well the company is managing its costs.
Revenue Growth
N/AAlthough specific revenue figures are not available, growth in revenue is essential for demonstrating market demand and operational success.
R&D Spending
N/AInvestment in research and development is critical for a biotech company to innovate and stay competitive in the market.
The print will turn on these two things.
Q1
What will the EPS be for Q1-2026?
Given Adaptive's history of beating EPS estimates, the market will closely watch this figure to gauge ongoing profitability.
Q2
What are the projections for revenue growth and R&D spending?
Investors need clarity on revenue growth and R&D investments to assess the company's future potential and market position.
Why consensus could be wrong
The Street may underestimate Adaptive's ability to leverage its innovative technology for revenue growth, especially in personalized medicine.
Supporting Evidence
Adaptive has consistently beaten EPS estimates, suggesting stronger operational performance than anticipated.
The company's focus on R&D could lead to breakthroughs that drive future revenue, which may not be fully reflected in current market expectations.
Recent industry trends indicate a growing demand for personalized medicine solutions, which could benefit Adaptive significantly.
Key Risk
If the company reports an EPS above $0.05, it could challenge current market skepticism and shift sentiment positively.
Pre-commit to what would confirm each case.
The market is weighing Adaptive's ability to maintain its positive EPS surprise trend against the backdrop of uncertain revenue growth.
Bull Confirmed If
An EPS of $0.05 or better would confirm strong operational performance and investor confidence.
Bear Confirmed If
An EPS of -$0.15 or worse would indicate potential issues with profitability and could lead to a sell-off.
Implied Move
±N/A
Historical Avg
±2.4%
There is currently no options market data available to gauge investor sentiment ahead of the earnings report.
Options are pricing ±15.5% while ADPT has averaged ±2.4% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Adaptive beats expectations and raises guidance, history suggests a potential stock increase of around 3.96%, confirming strong demand and operational efficiency.
In-Line / Cautious
If results are in line with expectations but lack clear guidance, the stock may experience muted movement as investors reassess future growth prospects.
Miss
If the company misses expectations, history suggests a potential decline of around 0.71%, indicating investor disappointment and concern over future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026